Table 2.
CYP2C19 genotypes distribution and P2Y12 receptor inhibitors selection.
| Items | RT n = 100 | GT n = 201 |
|---|---|---|
| CYP2C19 genotypes | ||
| LOF alleles carriers, N (%) | ||
| *2/*2 | NA | 20 (10.0) |
| *3/*3 | NA | 2 (1.0) |
| *2/*3 | NA | 15 (7.5) |
| *1/*2 | NA | 54 (26.9) |
| *1/*3 | NA | 24 (11.9) |
| Non-LOF alleles carriers, N (%) | ||
| *1/*1 | NA | 86 (42.8) |
| P2Y12 receptor inhibitors | ||
| Clopidogrel | 75 (75.0) | 86 (42.8) |
| Ticagrelor | 25 (25.0) | 115 (57.2) |
RT, routine treatment group; GT, genotype-guided treatment group; LOF, loss-of-function.